# A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors

> **NCT06248515** · PHASE2 · RECRUITING · sponsor: **Georgetown University** · enrollment: 18 (estimated)

## Conditions studied

- Thymoma
- Thymic Carcinoma

## Interventions

- **DRUG:** Sacituzumab govitecan-hziy

## Key facts

- **NCT ID:** NCT06248515
- **Lead sponsor:** Georgetown University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-25
- **Primary completion:** 2026-04
- **Final completion:** 2026-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06248515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06248515, "A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06248515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*